Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study
Authors' conclusion
In conclusion, FRAX reliably predicts incident fractures in men with prostate cancer.
Study context
- Population
- Men from the Manitoba Bone Mineral Density (BMD) Registry (1996–2018) undergoing DXA
- Participants
- 684 vs 8,608
- Exposure
- FRAX performance in men with vs without prostate cancer
- Prostate cancern = 684
- Without prostate cancern = 8,608reference
- Outcome
- Performance of FRAX (with and without BMD) for predicting incident MOF and hip fracture in men with prostate cancer: HR per SD increase in FRAX score
Methodological detailspopulation-based
- Population-based
Main finding
As reported in the abstract
Risk stratification by FRAX in men with prostate cancer (HR per SD increase in FRAX score)
Major osteoporotic fractures (MOF), FRAX with BMD: HR
1.91
95% CI 1.48–2.45
MOF, FRAX without BMD: HR
1.96
95% CI 1.43–2.69
Hip fracture, FRAX with BMD: HR
3.37
95% CI 1.90–6.01
Hip fracture, FRAX without BMD: HR
4.58
95% CI 2.17–9.67
Observational data: associations, not effects.
Further findings
Calibration: observed/predicted 10-year fracture probability ratios in men with prostate cancer
- MOF calibration ratio, with BMD
- 0.97
- Hip calibration ratio, with BMD
- 1.00
- MOF calibration ratio (second set, printed as "with BMD")
- 0.92
- Hip calibration ratio (second set, printed as "with BMD")
- 0.93
- Good agreement of observed 10-year fracture probability with FRAX with and without BMD
- Observed probability estimated with competing risk of mortality
Effect modification
- No effect modification by prostate cancer status or current androgen deprivation therapy
Original publication
Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study. J Bone Miner Res. Published 20 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →